Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
$1.124M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
279.0%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$34.35M
Q3 2024
Cash
Q3 2024
P/E
24.46
Nov 29, 2024 EST
Free Cash Flow
-$2.869M
TTM

Revenues

Revenues

Revenue YoY Change

No data

Revenues

Concept 2023 2022 2021
Revenue $50.00K $0.00
YoY Change

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021
Revenue $50.00K $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $315.0K $325.0K $992.4K
YoY Change -3.08% -67.25%
% of Gross Profit
Research & Development $1.147M $1.226M $1.080M
YoY Change -6.44% 13.51%
% of Gross Profit
Depreciation & Amortization $1.120M $1.113M $1.113M
YoY Change 0.63% 0.01%
% of Gross Profit
Operating Expenses $1.462M $1.551M $3.185M
YoY Change -5.74% -51.31%
Operating Profit -$4.028M -$3.404M
YoY Change 18.33%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $444.0K $462.0K -$135.2K
YoY Change -3.9% -441.67%
% of Operating Profit
Other Income/Expense, Net $52.00K $66.00K $77.35K
YoY Change -21.21% -14.67%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$4.407M -$7.876M -$3.243M
YoY Change -44.05% 142.85%
Income Tax -$621.0K -$1.395M
% Of Pretax Income
Net Earnings -$4.407M -$7.255M -$1.303M
YoY Change -39.26% 456.74%
Net Earnings / Revenue -14510.0%
Basic Earnings Per Share -$0.07 -$0.10
Diluted Earnings Per Share -$0.07 -$0.10 -$0.11

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

No data

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $1.000K $2.000K $45.98K
YoY Change -50.0% -95.65%
Cash & Equivalents $1.000K $2.000K $45.98K
Short-Term Investments
Other Short-Term Assets $0.00 $104.0K $43.60K
YoY Change -100.0% 138.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $332.0K $122.0K $286.9K
YoY Change 172.13% -57.47%
Property, Plant & Equipment $287.0K $276.0K
YoY Change 3.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $782.0K $4.817M
YoY Change -100.0% -83.76%
Other Assets
YoY Change
Total Long-Term Assets $44.30M $46.38M $56.14M
YoY Change -4.47% -17.39%
Total Assets $44.63M $46.50M $56.42M
YoY Change
Accounts Payable $832.0K $539.0K $115.1K
YoY Change 54.36% 368.49%
Accrued Expenses $230.0K $63.00K $5.350K
YoY Change 265.08% 1077.57%
Deferred Revenue
YoY Change
Short-Term Debt $12.07M $9.991M $12.52M
YoY Change 20.85% -20.22%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.14M $10.59M $12.64M
YoY Change 24.01% -16.22%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Liabilities $19.41M $16.94M $19.82M
YoY Change 14.59% -14.52%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding 60.25M shares 70.50M shares
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $27.495 Million

About IMPACT BIOMEDICAL INC.

Impact Biomedical Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Houston, Texas and currently employs 1 full-time employees. The company went IPO on 2024-09-16. Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The firm is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.

Industry: Pharmaceutical Preparations Peers: